Der Internist

, Volume 47, Issue 10, pp 1013–1023 | Cite as

Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen

Ein Update zur konventionellen Therapie
Schwerpunkt: Herzrhythmusstörungen

Zusammenfassung

Bei der Therapie supraventrikulärer Herzrhythmusstörungen haben sich in den letzten Jahren tief greifende Veränderungen ergeben: nichtmedikamentöse Strategien werden frühzeitiger eingesetzt und haben teilweise die medikamentösen Verfahren abgelöst. Häufig dient die medikamentöse Therapie, die über viele Jahre den Goldstandard darstellte, nur noch als Überbrückung bis zur kurativen Therapie durch Katheterablation des arrhythmogenen Substrates. Ein weiterer Schwerpunkt ist die adjuvante antiarrhythmische Therapie bei Patienten mit Cardioverter-Defibrillatoren. Bei der Akut- und Dauertherapie bestimmter Herzrhythmusstörungen, wie z. B. dem Vorhofflimmern, sind medikamentöse Ansätze unverzichtbar und weiterhin als primäre Therapie etabliert. Pharmaka, die zur Behandlung von Herzrhythmusstörungen eingesetzt werden, sind im Hinblick auf Struktur, Wirkmechanismus, potenzielle Nebenwirkungen und Interaktionen heterogen. Ihr Einsatz sollte nur bei strenger Indikationsstellung und engmaschiger kardiologischer Überwachung erfolgen. Angesichts ihrer häufig begrenzten therapeutischen Wirksamkeit ist die Nutzen-Risiko-Relation dieser Therapie besonders kritisch zu prüfen.

Schlüsselwörter

Rhythmusstörungen Ventrikulär Supraventrikulär Pharmakologisch Therapie 

Modern pharmacotherapy of supraventricular and ventricular cardiac arrhythmia

An update for conventional therapy

Abstract

Currently the pharmacological approach still represents the mainstay in the acute phase of arrhythmia management as well as in the chronic treatment phase of specific entities such as atrial fibrillation. However, non-pharmacological options have recently emerged as frequently used first-line tools for the treatment of various supraventricular and ventricular heart rhythm disturbances. Nevertheless, antiarrhythmic drug treatment is frequently used as a bridging or adjunctive therapy in conjunction with catheter ablation or implantable cardioverter defibrillators. Antiarrhythmic agents constitute a very heterogeneous group prone to various drug interactions and side-effects. Therefore, this article aims to summarise the most important facts and recent findings with regard to appropriate contemporary pharmacological therapy of atrial and ventricular arrhythmias in clinical practice.

Keywords

Arrhythmia Ventricular Supraventricular Pharmacological therapy Therapy 

Notes

Interessenkonflikt

Keine Angaben

Literatur

  1. 1.
    Alboni P, Botto GL, Baldi N et al. (2004) Outpatient treatment of recent-onset atrial fibrillation with the „pill-in-the-pocket“ approach. N Engl J Med 351(23): 2384–2391CrossRefPubMedGoogle Scholar
  2. 2.
    Anderson JL, Gilbert EM, Alpert BL et al. (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80(6): 1557–1570PubMedGoogle Scholar
  3. 3.
    Bardy GH, Lee KL, Mark DB et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3): 225–237CrossRefPubMedGoogle Scholar
  4. 4.
    Bianconi L, Mennuni M (1998) Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. Am J Cardiol 82(5): 584–588CrossRefPubMedGoogle Scholar
  5. 5.
    Bigger JT Jr, Fleiss JL, Kleiger R et al. (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69(2): 250–258PubMedGoogle Scholar
  6. 6.
    Blomstrom-Lundqvist C, Scheinman MM et al. (2003) ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in collaboration with NASPE-Heart Rhythm Society. Eur Heart J 24(20): 1857–1897CrossRefGoogle Scholar
  7. 7.
    Capucci A, Boriani G, Rubino I et al. (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 43(3): 305–313CrossRefPubMedGoogle Scholar
  8. 8.
    Connolly SJ, Hoffert DL (1989) Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 63(12): 817–819CrossRefPubMedGoogle Scholar
  9. 9.
    Connolly SJ, Gent M, Roberts RS et al. (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101(11): 1297–1302PubMedGoogle Scholar
  10. 10.
    Connolly SJ, Hallstrom AP, Cappato R et al. (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21(24): 2071–2078CrossRefPubMedGoogle Scholar
  11. 11.
    Connolly SJ, Dorian P, Roberts RS et al. (2006) Comparison of (beta)-Blockers, Amiodarone Plus (beta)-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: a randomized trial. JAMA 295(2): 165–171CrossRefPubMedGoogle Scholar
  12. 12.
    Danias P, Caulfield TA, Weigner MJ et al. (1998) Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am College Cardiol 31(3): 588–592CrossRefGoogle Scholar
  13. 13.
    Echt DS, Liebson PR, Mitchell LB et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12): 781–788PubMedGoogle Scholar
  14. 14.
    Epstein AE, Hallstrom AP, Rogers WJ et al. (1993) Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 270(20): 2451–2455CrossRefPubMedGoogle Scholar
  15. 15.
    Fetsch T, Bauer P, Engberding R et al. (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25(16): 1385–1394CrossRefPubMedGoogle Scholar
  16. 15b.
    Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC (2006) Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Journal of the American College of Cardiology 2006 August 15; 48(4): 854–906Google Scholar
  17. 16.
    Gilman JK, Jalal S, Naccarelli GV (1994) Predicting and preventing sudden death from cardiac causes. Circulation 90(2): 1083–1092PubMedGoogle Scholar
  18. 17.
    Go AS, Hylek EM, Phillips KA et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18): 2370–2375CrossRefPubMedGoogle Scholar
  19. 18.
    Goldberg AS, Bathina MN, Mickelsen S et al. (2002) Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 89(9): 1120–1123CrossRefPubMedGoogle Scholar
  20. 19.
    Greene HL (1993) The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 72(16): 70F-4FCrossRefPubMedGoogle Scholar
  21. 20.
    Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244): 1789–1794CrossRefPubMedGoogle Scholar
  22. 21.
    Hohnloser SH, Singh BN (1995) Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6(10 Pt 2): 920–936PubMedGoogle Scholar
  23. 22.
    Hsu LF, Jais P, Sanders P et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351(23): 2373–2383CrossRefPubMedGoogle Scholar
  24. 23.
    Joseph AP, Ward MR (2000) A prospective, randomized controlled trial comparing the efficacy and safety of Sotalol, Amiodarone, and Digoxin for the reversion of new-onset atrial fibrillation. Ann Emergency Med 36(1): 1–9CrossRefGoogle Scholar
  25. 24.
    Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N (1990) Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990 82(6): 1932–1939Google Scholar
  26. 25.
    Kirchhof P, Fetsch T, Hanrath P et al. (2005) Targeted pharmacological reversal of electrical remodeling after cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 150(5): 899CrossRefGoogle Scholar
  27. 26.
    Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 102(7): 748–754PubMedGoogle Scholar
  28. 27.
    Kuhlkamp V, Mewis C, Mermi J et al. (1999) Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am College Cardiol 33(1): 46–52CrossRefGoogle Scholar
  29. 28.
    Kuhlkamp V, Schirdewan A, Stangl K et al. (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36(1): 139–146CrossRefPubMedGoogle Scholar
  30. 29.
    Li D, Shinagawa K, Pang L et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104(21): 2608–2614PubMedGoogle Scholar
  31. 30.
    Madrid AH, Peng J, Zamora J et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27(10): 1405–1410CrossRefPubMedGoogle Scholar
  32. 31.
    Marcus FI (1990) The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 66(3): 366–367CrossRefPubMedGoogle Scholar
  33. 32.
    Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329(7): 452–458CrossRefPubMedGoogle Scholar
  34. 33.
    Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329(7): 445–451CrossRefPubMedGoogle Scholar
  35. 34.
    Moss AJ, Zareba W, Hall WJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12): 877–883CrossRefPubMedGoogle Scholar
  36. 35.
    Murray KT (1998) Ibutilide. Circulation 97(5): 493–497PubMedGoogle Scholar
  37. 36.
    Natale A, Newby KH, Pisano E et al. (2000) Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am College Cardiol 35(7): 1898–1904CrossRefGoogle Scholar
  38. 37.
    Page RL, Wilkinson WE, Clair WK et al. (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89(1): 224–227PubMedGoogle Scholar
  39. 38.
    Pantos C, Mourouzis I, Delbruyere M et al. (2002) Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur J Pharmacol 444(3): 191–196CrossRefPubMedGoogle Scholar
  40. 39.
    Pedersen OD, Bagger H, Keller N et al. (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 104(3): 292–296PubMedGoogle Scholar
  41. 40.
    Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10): 669–677PubMedGoogle Scholar
  42. 41.
    Roy D, Talajic M, Dorian P et al. (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342(13): 913–920CrossRefPubMedGoogle Scholar
  43. 42.
    Singh SN, Singh BN, Reda DJ et al. (2003) Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 92(4): 468–472CrossRefPubMedGoogle Scholar
  44. 43.
    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337(22): 1576–1583CrossRefPubMedGoogle Scholar
  45. 44.
    The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23): 1825–1833PubMedGoogle Scholar
  46. 45.
    Van Gelder IC, Hagens VE, Bosker HA et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23): 1834–1840CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • D. Steven
    • 1
  • B. Lutomsky
    • 1
  • T. Rostock
    • 1
  • S. Willems
    • 1
  1. 1.Klinik für Kardiologie/AngiologieUniversitäres HerzzentrumHamburgDeutschland

Personalised recommendations